NT-proBNP to Assess Trastuzumab-induced Cardiotoxicity

Abroad (travel likely)Recruiting

Conditions

Cardiotoxicity · Breast Cancer · Treatment Side Effects

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Jubileumskliniken, Sahlgrenska University Hospital, Gothenburg, Sweden
Contact: Study coordinator (Daniel Giglio, Assoc Prof) · daniel.giglio@pharm.gu.se · +46(0)31-342 16 06

Study leads

Daniel Giglio, Assoc Prof
Principal Investigator
Sahlgrenska University Hospital/University of Gothenburg
Barbro Linderholm, Assoc Prof
Principal Investigator
Sahlgrenska University Hospital/University of Gothenburg

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

The STOP-MED CTRCD Trial

Heart Failure · Cardiotoxicity · Cardiac Toxicity

Abroad (travel likely)RecruitingPHASE4

Los Angeles, United States · Boston, United States

Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction

Anthracycline Related Cardiotoxicity in Breast Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Lubbock, United States

Global Cardio Oncology Registry

Breast Cancer · Hematologic Malignancy · Immune Checkpoint Inhibitor-Related Myocarditis

Abroad (travel likely)Recruiting

Weston, United States

Breast cancEr, FITness and ExeRcise for Heart Health: The BE-FITTER Study

Breast Cancer · Disability Physical · Heart Failure

Abroad (travel likely)Recruiting

Edmonton, Canada